Literature DB >> 7889920

Distribution of equid herpesvirus-1 (EHV-1) in the respiratory tract of ponies: implications for vaccination strategies.

J H Kydd1, K C Smith, D Hannant, G J Livesay, J A Mumford.   

Abstract

Twelve adult ponies and 2 conventional foals were exposed to 10(6.6) TCID50 of Equid herpesvirus-1 (EHV-1), strain Ab4 and samples of respiratory tract tissues were recovered. Infectious virus in tissue homogenates was detected using susceptible cell monolayers and expression of viral antigens was monitored using indirect immunoperoxidase histochemistry of paraffin sections. The results illustrated the rapid dissemination of EHV-1 throughout the respiratory tract, with early replication in the lungs one day after exposure. Endothelial cell infection was prominent in all areas of the nasopharynx by Day 4 emphasising the role of endotheliotropism and viraemia in dissemination of this virus to sites of secondary replication. Clinical disease in the adult ponies was mild.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7889920     DOI： 10.1111/j.2042-3306.1994.tb04051.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN： 0425-1644            Impact factor:   2.888


  9 in total

1.  An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease.

Authors:  Christiane L Schnabel; Susanna Babasyan; Alicia Rollins; Heather Freer; Christine L Wimer; Gillian A Perkins; Fahad Raza; Nikolaus Osterrieder; Bettina Wagner
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

2.  Pathogenesis and clinical signs of equine herpesvirus-1 in experimentally infected ponies in vivo.

Authors:  G A Sutton; L Viel; P S Carman; B L Boag
Journal:  Can J Vet Res       Date:  1998-01       Impact factor: 1.310

3.  Effect of a Histone Demethylase Inhibitor on Equine Herpesvirus-1 Activity In Vitro.

Authors:  Rebecca L Tallmadge; Emilija Žygelytė; Gerlinde R Van de Walle; Thomas M Kristie; M Julia B Felippe
Journal:  Front Vet Sci       Date:  2018-03-12

4.  Deletion of the ORF2 gene of the neuropathogenic equine herpesvirus type 1 strain Ab4 reduces virulence while maintaining strong immunogenicity.

Authors:  Christiane L Schnabel; Christine L Wimer; Gillian Perkins; Susanna Babasyan; Heather Freer; Christina Watts; Alicia Rollins; Nikolaus Osterrieder; Bettina Wagner
Journal:  BMC Vet Res       Date:  2018-08-22       Impact factor: 2.741

Review 5.  EHV-1: A Constant Threat to the Horse Industry.

Authors:  Fatai S Oladunni; David W Horohov; Thomas M Chambers
Journal:  Front Microbiol       Date:  2019-12-03       Impact factor: 5.640

6.  Identification of a New Equid Herpesvirus 1 DNA Polymerase (ORF30) Genotype with the Isolation of a C2254/H752 Strain in French Horses Showing no Major Impact on the Strain Behaviour.

Authors:  Gabrielle Sutton; Côme Thieulent; Christine Fortier; Erika S Hue; Christel Marcillaud-Pitel; Alexis Pléau; Alain Deslis; Edouard Guitton; Romain Paillot; Stéphane Pronost
Journal:  Viruses       Date:  2020-10-13       Impact factor: 5.048

7.  A Live-Attenuated Equine Influenza Vaccine Stimulates Innate Immunity in Equine Respiratory Epithelial Cell Cultures That Could Provide Protection From Equine Herpesvirus 1.

Authors:  Lila M Zarski; Wendy E Vaala; D Craig Barnett; Fairfield T Bain; Gisela Soboll Hussey
Journal:  Front Vet Sci       Date:  2021-06-10

8.  Replication characteristics of equine herpesvirus 1 and equine herpesvirus 3: comparative analysis using ex vivo tissue cultures.

Authors:  Haileleul Negussie; Yewei Li; Tesfaye Sisay Tessema; Hans J Nauwynck
Journal:  Vet Res       Date:  2016-01-15       Impact factor: 3.683

9.  The deletion of the ORF1 and ORF71 genes reduces virulence of the neuropathogenic EHV-1 strain Ab4 without compromising host immunity in horses.

Authors:  Christine L Wimer; Christiane L Schnabel; Gillian Perkins; Susanna Babasyan; Heather Freer; Alison E Stout; Alicia Rollins; Nikolaus Osterrieder; Laura B Goodman; Amy Glaser; Bettina Wagner
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.